Table 2.
Expression of necroptotic factors in cancer and its influence on cancer prognosis
| Cancer Type | Expression of Necroptotic Factors | The Influence on Prognosis | Reference |
|---|---|---|---|
| Breast Cancer | decreased RIPK3 expression | worse prognosis | [7, 65] |
| Colorectal Cancer | decreased RIPK3 expression; decreased MLKL expression | reduced DFS and OS; reduced OS | [12, 66, 67] |
| Acute Myeloid Leukemia | decreased RIPK3 expression | accelerated leukemogenesis and worse survival | [11, 68] |
| Melanoma |
decreased RIPK3 expression; decreased CYLD expression |
not mentioned; enhanced tumor progression and metastasis | [69, 70] |
| Head and Neck Squamous Cell Carcinoma | decreased RIPK1 expression | enhanced tumorigenesis | [9] |
| Chronic Lymphocytic Leukemia | decreased CYLD expression | reduced OS | [71] |
| Glioblastoma | increased RIPK1 expression | worse prognosis | [10] |
| Lung Cancer | increased RIPK1 expression | promoted oncogenesis | [72] |
| Pancreatic Cancer | increased expression of RIPK1, RIPK3, FADD and MLKL | promoted oncogenesis | [64, 73] |
| Gastric Cancer | decreased MLKL expression | reduced OS | [74] |
| Ovarian Cancer | Decreased MLKL expression | reduced OS | [75] |
| Cervical Squamous Cell Carcinoma | decreased MLKL expression | reduced OS | [76] |